Answers are grounded in this paper and cite their sources.
Randomized trial shows adjunctive agents reduce gingival inflammation in gingivitis, suggesting enhanced oral care effectiveness.
AIM: In systemically healthy humans with gingivitis, what is the efficacy of active agents compared to negative control/placebo when used adjunctively to mechanical biofilm control in terms of changes in gingivitis/bleeding indices and/or disease resolution in randomised controlled clinical trials (RCTs) with at least 3-months follow-up? MATERIAL AND METHODS: Electronic searches, study selection, data extraction, risk of bias analysis, meta-analyses and certainty of the evidence were performed (GRADE). RESULTS: = 20; WMD = 10.79%; p < 0.001). Gingivitis resolution was rarely determined. Prevalence of local adverse effect (tooth-related and soft-tissue-related) varied from 0% to 13.1%. Systemic effects were scarcely evaluated. CONCLUSIONS: In adults with gingivitis, the adjunctive use of specific antiseptics determined higher reduction of gingival inflammation at 3 months (moderate evidence for stannous fluoride and low-to-very low for chlorhexidine, essential oils or cetylpyridinium chloride [CPC]) and 6 months (moderate for chlorhexidine, low for CPC and very low for essential oils) over placebo/negative controls. Adverse effects are neither frequently nor extensively reported. Gingivitis resolution is rarely reported and achieved.
No takes yet. Share an insight, caveat, or question.
Figuero et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: